Newsletters

[Phytotherapy Research] To elucidate the underlying antitumor mechanism of lambertianic acid (LA) derived from Pinus koraiensis, the role of cancer metabolism related molecules was investigated in the apoptotic effect of LA in DU145 and PC3 prostate cancer cells.

[Frontiers In Pharmacology] Super enhancer-associated genes and transcription factors were identified from a cell line of metastatic castration-resistant prostate cancer (mCRPC) by the CUT&Tag assay. Differentially expressed genes between mCRPC and primary prostate cancer samples in the GSE35988 dataset were identified.

[Frontiers In Oncology] To facilitate the practical application of human embryonic stem cells (hESCs), scientists established a co-culture system consisting of prostate cancer cell lines and hESCs and investigated the antitumor activity of the supernatant of the co-culture system in vitro and in vivo.

[Frontiers In Oncology] Researchers investigated the expression and clinical prognosis of charged multivesicular protein (CHMP) 4C and explored its potential regulatory mechanism in prostate cancer.

[Prostate Cancer and Prostatic Diseases] Prostatic tissue from the primary site, and adjacent non-cancerous tissue was obtained from four patients with localized disease undergoing radical prostatectomy. Epithelial cell outgrowths were immortalized with human papillomavirus type 16 E6 and E7 to establish monoclonal cell lines.

[PROTEOMICS] Investigators used a cellular-based proteomics approach to more holistically profile both the intracellular and extracellular proteome of prostate cancer. Their workflow was generated in such a manner that multiple experimental conditions could be observed with the opportunity for high throughput integration.

[Journal Of Cellular And Molecular Medicine] The authors evaluated the inhibitory effects of quercetin against prostate malignancy in vitro and the underlying resistance mechanism. IC50 values of quercetin were determined by MTT assay.

[Molecular Carcinogenesis] Scientists showed that co-treatment with abiraterone and ICG001, a β-catenin inhibitor, overcame therapeutic resistance and significantly inhibited markers of stem cell and cellular proliferation in abiraterone-resistant prostate cancer cells.

[Discover Oncology] Investigators detected the expression level of XPO6 in prostate cancer tissues by immunohistochemistry and analyzed the correlation between clinicopathological characteristics and XPO6 level based on TCGA database.

[The Prostate] PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases. Four treatment groups were created: vehicle, docetaxel (5 mg/kg), balixafortide (20 mg/kg), and combination of both.

[Frontiers In Oncology] The authors summarize the prevalence of DNA damage response (DDR) alterations in primary and advanced prostate cancer and discuss the impact of alterations in the DDR pathway on aggressive disease phenotype, prognosis, and the association of germline pathogenic alterations in DDR genes with risk of developing prostate cancer.

[University of Wisconsin] University of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute for research initiatives to advance new prostate cancer treatments.